Injection of paraoxonase 1 (PON1) to mice stimulates their HDL and macrophage antiatherogenicity

被引:13
|
作者
Rosenblat, Mira [1 ]
Volkova, Nina [1 ]
Aviram, Michael [1 ]
机构
[1] Technion Fac Med, Lipid Res Lab, Rappaport Family Inst Res Med Sci, Rambam Med Ctr, IL-31096 Haifa, Israel
关键词
Paraoxonase1; macrophages; HDL; cholesterol metabolism; oxidation; DENSITY-LIPOPROTEIN OXIDATION; SERUM PARAOXONASE; CHOLESTEROL-BIOSYNTHESIS; LIPID PEROXIDES; CORONARY; BINDING; CELLS;
D O I
10.1002/biof.188
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We analyzed, for the first time, the effects of recombinant PON1 (rePON1) intraperitoneal injection to C57BL/6 mice on their HDL and macrophage antiatherogenic properties. Thioglycolate-treated mice were injected with either saline (Control), or rePON1 (50 mu g/mouse), and 20 H post injection, their blood samples and peritoneal macrophages (MPM) were collected. A significant increase in serum and HDL-PON1 arylesterase and lactonase activities was noted. Similarly, a significant increment, by 3.8 and 2.8 fold, in MPM-PON1 arylesterase and lactonase activities, respectively, as compared to the activities in control MPM was observed. The HDL from rePON1-injected mice was resistant to oxidation by copper ions as compared to control HDL. Furthermore, enrichment of the mouse HDL with rePON1 increased its ability to induce cholesterol efflux from J774A.1 macrophage cell line, and to inhibit macrophage-mediated LDL oxidation. In MPM from rePON1-injected mice vs. control MPM, there was a significant reduction in cholesterol mass, by 42%, in association with inhibition in cellular cholesterol biosynthesis rate, by 33%, and with significant stimulation, by 65%, of human HDL-mediated cholesterol efflux from the cells. We conclude that rePON1 injection to mice improved the mice HDL and MPM antiatherogenic properties, and these effects could probably lead to attenuation of atherosclerosis development.
引用
收藏
页码:462 / 467
页数:6
相关论文
共 50 条
  • [1] Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice
    Rozenberg, O
    Shih, DM
    Aviram, M
    ATHEROSCLEROSIS, 2005, 181 (01) : 9 - 18
  • [2] Macrophage paraoxonase 1 (PON1) binding sites
    Efrat, Michal
    Aviram, Michael
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 376 (01) : 105 - 110
  • [3] HDL - ASSOCIATED PARAOXONASE 1 (PON1) ATTENUATES MACROPHAGE FOAM CELL FORMATION AND ATHEROGENESIS
    Aviram, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [4] Serum paraoxonase PON1 and its interactions with HDL
    Gaidukov, Leonid A.
    Aharoni, Amir
    Khersonsky, Olga
    Tawfik, Dan S.
    FASEB JOURNAL, 2008, 22
  • [5] Paraoxonase 1 (PON1) reduces macrophage inflammatory responses
    Aharoni, Saar
    Aviram, Michael
    Fuhrman, Bianca
    ATHEROSCLEROSIS, 2013, 228 (02) : 353 - 361
  • [6] Paraoxonase 1 (PON1) inhibits monocyte-to-macrophage differentiation
    Rosenblat, Mira
    Volkova, Nina
    Ward, John
    Aviram, Michael
    ATHEROSCLEROSIS, 2011, 219 (01) : 49 - 56
  • [7] Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: Studies in PON1-knockout mice
    Rozenberg, O
    Rosenblat, M
    Coleman, R
    Shih, DM
    Aviram, M
    FREE RADICAL BIOLOGY AND MEDICINE, 2003, 34 (06) : 774 - 784
  • [8] Glucose inactivates paraoxonase 1 (PON1) and displaces it from high density lipoprotein (HDL) to a free PON1 form
    Rosenblat, Mira
    Sapir, Orly
    Aviram, Michael
    PARAOXNASES: THEIR ROLE IN DISEASE DEVELOPMENT AND XENOBIOTIC METABOLISM, 2008, 6 : 35 - 49
  • [9] Pharmacological Interactions of Paraoxonase 1 (PON1): A HDL-Bound Antiatherogenic Enzyme
    Mahrooz, Abdolkarim
    CURRENT CLINICAL PHARMACOLOGY, 2016, 11 (04): : 259 - 264
  • [10] The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates β-cell insulin release
    Koren-Gluzer, Marie
    Aviram, Michael
    Meilin, Edna
    Hayek, Tony
    ATHEROSCLEROSIS, 2011, 219 (02) : 510 - 518